Toceranib targets receptor tyrosine kinases, including C-KIT, VEGFR-2, PDGFa/b, and CSF-1 (colony stimulating factor–1) and is used as a first-line treatment for dogs with mast cell tumors [63]. This evidence concerns the gene CSF1 and mast cell neoplasm.